Iku Shirasugi, Akira Onishi, Keisuke Nishimura, Wataru Yamamoto, Kosaku Murakami, Hideo Onizawa, Yuichi Maeda, Kosuke Ebina, Yonsu Son, Hideki Amuro, Masaki Katayama, Ryota Hara, Koji Nagai, Yuri Hiramatsu, Motomu Hashimoto, Tadashi Okano, Toshihisa Maeda, Shinya Hayashi, Sho Sendo, Sadao Jinno, Yuzuru Yamamoto, Hirotaka Yamada, Yo Ueda, Jun Saegusa
AIM: To investigate the association of large joint involvement (LJI) with disease activity and drug retention in patients with rheumatoid arthritis (RA) who started receiving a biological disease-modifying antirheumatic drug or Janus kinase inhibitor. METHODS: Patients with RA from a Japanese multicenter observational registry were enrolled. Our definition of large joints included the shoulder, elbow, hip, knee, and ankle joints. Linear mixed-effects models were used to examine changes in the clinical disease activity index (CDAI) score at Week 24 as the primary outcome, and drug retention rates were compared between patients with and without LJI using Cox proportional hazards models...
March 2024: International Journal of Rheumatic Diseases